NASDAQ Careers: Find a Job Now
Web NASDAQ.com
Search
Save my stocks for next time

Symbol List ViewsSymbol List Views

Stock DetailsStock Details

Stock DetailsCHARTS

Stock DetailsCOMPANY NEWS

Stock DetailsSTOCK ANALYSIS

Stock DetailsFUNDAMENTALS

Stock DetailsHOLDINGS

ARIA: Stock Quote & Summary Data

$ 2.28 0.05 2.24%
Feb. 9, 2010 12:58 ET Market Open
Update Quotes: . Updates every 7 Seconds.
ARIAD Pharmaceuticals, Inc.
ARIA | ARIAD Pharmaceuticals, Inc. | Common Stock | Market : NASDAQ-GM

Last Sale
Change Net / %
Best Bid / Ask
1y Target Est: $ 4.00
Today's High / Low  / 
Share Volume
50 Day Avg. Daily Volume 1,794,521
Previous Close $ 2.23
52 Wk High / Low $ 3.48 / $ 0.97
Shares Outstanding 108,958,000
Market Value $ 248,424,240
P/E Ratio NE
Forward P/E (1yr) NE
Earnings Per Share $ -0.95
Annualized Dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield N/A
Beta 0.63
NASDAQ Official Open Price: $ 2.25
Date of NASDAQ Official Open Price: Feb. 9, 2010
NASDAQ Official Close Price: $ 2.23
Date of NASDAQ Official Close Price: Feb. 8, 2010

 Intraday Chart

5d | 1m | 6m | 12m | More Charting

Have a Question About ARIA?

Ask your question about about ARIAD Pharmaceuticals, Inc. (ARIA) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!

Hot Topics in NASDAQ Answers

The most popular questions & answers in the
NASDAQ Answers Community:


 Company Description (as filed with the SEC)

The following Business Section contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors (see Part I, Item 1A: Risk Factors). Unless the content requires otherwise, references to “ARIAD,” “we,” “our,” and “us,” in this Annual Report on Form 10-K refer to ARIAD Pharmaceuticals, Inc. and our subsidiaries. Overview Our Business and Strategy We are engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. We are developing a comprehensive approach to patients with cancer that addresses the greatest medical need — aggressive and advanced-stage cancers for which current treatments are inadequate.  ... More ...  

Get ETF News, Commentary, Tools & more...

Visit the new NASDAQ.com ETFs hub Now

 Company News for ARIA

ARIAD Pharma To Present At The 12th Annual BIO CEO & Investor Conference At 3:30 PM, ET
- RTT News  02/08/2010 1:05PM
ARIAD to Present at the 12th Annual BIO CEO & Investor Conference
- Business Wire  01/28/2010 7:35AM
ARIAD To Present At The 28th Annual J.P. Morgan Healthcare Conference; Webcast At 10:30 AM, ET
- RTT News  01/13/2010 9:36AM
ARIAD to Present at the 28th Annual J.P. Morgan Healthcare Conference
- Business Wire  01/04/2010 7:35AM
Top Ten '09 Clone Portfolios
- Seeking Alpha  01/03/2010 9:27AM
 

Consensus Recommendation


Analyst Info

Annual EPS Est: $ -0.84
Quarterly EPS Est: $ -0.17
PEG Ratio: N/A
Mean Recommendation:
View Summary/View All
1.44